^
    over4years
    Dynamic evolution of clonal composition and neoantigen landscape in recurrent metastatic melanoma with a rare combination of driver mutations. (PubMed, J Invest Dermatol)
    The mutant proteins cooperatively activate the MAP kinase signalling pathway confirming they are potential driver mutations of this tumour. We hence describe the long-term genetic evolution of cutaneous metastatic melanoma characterised by an unexpected phenotypic stability and neoantigen driven clonal selection.
    Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF mutation • BRAF fusion • MAP2K1 F53Y